The pharmaceutical company Roche has received positive long-term data from a clinical trial in patients with early-stage breast cancer, showing a significant benefit in overall survival.
The “Katherine” study examined the effectiveness and safety of Kadcyla compared to Herceptin as adjuvant therapy, Roche announced.
The data showed a sustained benefit for Kadcyla, as it reduced the risk of disease recurrence or death from any cause by 46 percent compared to Herceptin. After three years, breast cancer had not recurred in 88.3 percent of patients treated with Kadcyla, compared to 77 percent of patients treated with Herceptin.
Approved in 113 countries, Kadcyla is considered the standard of care for patients with early-stage, HER2-positive breast cancer who have residual invasive disease after preoperative treatment.
By Andrea Figueras
BASEL (Dow Jones)
Selected leverage products on Roche
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Roche
The leverage must be between 2 and 20
Advertising